Katalog

The system is designed to give buyers clear and actionable information: ⬢ Product name + strength + dosage form: for example, "Amoxicillin 500 mg tablets" or "Atorvastatin 20 mg capsules." ⬢ Market: a dropdown selector covering global regions and key countries. ⬢ Offer type: choose whether the listing is manufacturing only, distribution rights only, marketing authorization (MA), or combinations such as MA + Manufacturing and MA + Distribution rights.

Licensing opportunities are not limited to one geography. MAI CDMO Network covers a broad spectrum of territories, allowing users to filter by region or key country: ⬢ Global: products available for worldwide licensing and distribution. ⬢ European Union (EU): suitable for centralized or decentralized EMA submissions. ⬢ European Economic Area (EEA): extending coverage beyond the EU to additional European markets. ⬢ North America (USA, Canada, Mexico): includes FDA and Health Canada compliant dossiers and distribution opportunities. ⬢ Latin America (LATAM): markets like Brazil, Argentina, and Mexico with growing demand for generic drugs for licensing. ⬢ Middle East & North Africa (MENA): regional authorizations and distribution rights adapted to local agencies. ⬢ Sub-Saharan Africa: diverse opportunities for essential medicines and ready-to-license pharmaceuticals. ⬢ Asia-Pacific (APAC): fast-growing markets such as China, India, Japan, and Australia. ⬢ CIS countries: including Russia and neighboring markets with specific regulatory frameworks. Key individual markets are also listed for more precise targeting: United States, Canada, Mexico, Brazil, Argentina, United Kingdom, Germany, France, Italy, Spain, China, India, Japan, and Australia. This granularity makes it possible to match pharmaceutical licensing opportunities to your exact territory needs.

Each listing specifies the offer type so you can identify what is on the table: ⬢ Manufacturing only: contract manufacturing without licensing or distribution rights. ⬢ Distribution rights only: commercial rights to sell in defined territories. ⬢ Marketing Authorisation (MA): access to an existing MA or the ability to license it. ⬢ Manufacturing + Distribution rights: supply plus sales authorization in chosen markets. ⬢ MA + Manufacturing: licensing of the authorization combined with production rights. ⬢ MA + Manufacturing + Distribution rights: a complete package including regulatory, supply, and commercialization. This transparent categorization helps companies quickly evaluate whether a product is aligned with their business model, whether that means sourcing from a CDMO, obtaining distribution rights, or acquiring marketing authorization licensing.

The MAI CDMO Network licensing catalog is designed for: ⬢ Pharma companies: to expand their pipeline with in-licensed assets and accelerate market entry. ⬢ Distributors: to secure distribution rights in their regions with minimal lead time. ⬢ CDMOs and manufacturers: to showcase products where they can provide manufacturing services. ⬢ Startups and smaller firms: to use dossier licensing plus CDMO manufacturing for quick launches.

By consolidating pharma products for licensing into one searchable database, MAI CDMO Network reduces the time and complexity of identifying new opportunities. The structure � product name, strength, dosage form, market, and offer type � provides clarity and comparability. Whether you are seeking MA/MAH licensing, dossier licensing, or distribution rights, the platform makes it simple to find, filter, and connect with the right partner. With global coverage spanning EU, EEA, North America, LATAM, MENA, Sub-Saharan Africa, APAC, CIS, and key countries such as US, UK, Germany, China, India, Japan and more, this catalog is your gateway to ready-to-license pharmaceuticals worldwide.